Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes  

作　　者：Yang Liu Jianying Liu Jing Zou Birte Kalveram Rafael R.G.Machado Ping Ren Sina Tureli Derek J.Smith Scott C.Weaver Xuping Xie Pei-Yong Shi 

机构地区：[1]Department of Biochemistry and Molecular Biology,University of Texas Medical Branch,Galveston,TX,USA [2]Institute of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,China [3]Department of Microbiology and Immunology,University of Texas Medical Branch,Galveston,TX,USA [4]Department of Pathology,University of Texas Medical Branch,Galveston,TX,USA [5]Center for Pathogen Evolution,Department of Zoology,University of Cambridge,Cambridge,UK [6]Sealy Institute for Drug Discovery,University of Texas Medical Branch,Galveston,TX,USA [7]Sealy Center for Structural Biology&Molecular Biophysics,University of Texas Medical Branch,Galveston,TX,USA

出　　处：《Signal Transduction and Targeted Therapy》2022年第9期3202-3205,共4页信号转导与靶向治疗（英文）

摘　　要：Dear Editor The rapid evolution of SARS-CoV-2 mandates a better under-standing of cross-neutralization and cross-protection among variants.Such information is essential to guide vaccine strategy and public policy.To examine the cross-protection among different variant spikes,we initially prepared four chimeric SARS-CoV-2 viruses(Fig.1a),each bearing the spike gene from Alpha,Beta,Gamma,or Epsilon in the backbone of USA-WA1/2020[isolated in January 2020 and defned as wild-type(WT)].

关 键 词：vaccine CROSS BACKBONE 

分 类 号：R563.1[医药卫生—呼吸系统]